PerkinElmer today announced that it has entered into a definitive agreement to acquire Tulip Diagnostics Private Ltd. Based in Goa, India, Tulip is one of the country's largest domestic providers of in-vitro diagnostic reagents, kits and instruments to an expansive customer base of diagnostic labs and government and private healthcare facilities. Tulip's solutions include products for the prevention, screening and diagnosis of infectious diseases such as malaria, HIV and hepatitis.
"As we continue to build out our Diagnostics business on a global scale, this acquisition further positions PerkinElmer for long-term growth in emerging market diagnostics, an attractive end market and key area of focus for us," said Prahlad Singh, Senior Vice President and President, Diagnostics, PerkinElmer. "We are committed to expanding our infectious disease screening menu and capabilities, and Tulip's product portfolio, channel access, and broad footprint provide the key enablers to help accelerate our growth in this important market."
PerkinElmer offers a global diagnostics portfolio focused on reproductive health, infectious disease screening and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings. The transaction is currently anticipated to close in the first quarter of 2017.
Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.